Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 10/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 9/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6522250 | 1.00 | ITGA4 (0.41) | ITGA4ITGB1HDAC1HDAC6CHEK1 | |
| SCHEMBL4675410 | 0.89 | ITGA4 (0.44) | ITGA4ITGB1HDAC1HDAC6CHEK1 | |
| SCHEMBL4676129 | 0.89 | ITGA4 (0.44) | ITGA4ITGB1HDAC1HDAC6CHEK1 | |
| SCHEMBL4675407 | 0.89 | ITGA4 (0.44) | ITGA4ITGB1HDAC1HDAC6CHEK1 | |
| SCHEMBL4676138 | 0.89 | ITGA4 (0.44) | ITGA4ITGB1HDAC1HDAC6CHEK1 | |
| SCHEMBL4675238 | 0.85 | ITGA4 (0.40) | ITGA4ITGB1HDAC1HDAC6CHEK1 | |
| SCHEMBL4675244 | 0.85 | ITGA4 (0.40) | ITGA4ITGB1HDAC1HDAC6CHEK1 | |
| SCHEMBL6163582 | 0.83 | ITGA4 (0.40) | ITGA4ITGB1HDAC1HDAC6CHEK1 | |
| SCHEMBL6163576 | 0.83 | ITGA4 (0.40) | ITGA4ITGB1HDAC1HDAC6CHEK1 | |
| SCHEMBL4671585 | 0.83 | ITGA4 (0.46) | ITGA4ITGB1CHEK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962937-B2 | Imidazolidine derivatives, their preparation and their use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-11-08 | — | — | US | disclosed |
| EP-1414444-A1 | NOVEL IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VLA-4 ANTAGONISTS | Aventis Pharma Deutschland GmbH (DE) | 2004-05-06 | — | — | EP | disclosed |
| US-20030109497-A1 | Novel imidazolidine derivatives, their preparation and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-06-12 | — | — | US | disclosed |
| WO-2003011288-A1 | NOVEL IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VLA-4 ANTAGONISTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109497-A1 | Novel imidazolidine derivatives, their preparation and their use | VCAM1, ITGA1, ITGA4 | ITGA4 3/4885ITGB1 5/4885HDAC1 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.